GYRE Earnings & Financial Statements
Gyre Therapeutics, Inc.
$6.47
-$0.24(-3.58%)
40
Overall
40
Value
36
Tech
44
Quality
Market Cap
$721.47M
Volume
162.85K
52W Range
$5.44 - $9.42
Target Price
$18.67
GYRE earnings and financial statements: Gyre Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
GYRE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $116.59M | $105.76M | $113.45M | $102.29M | $7.34M |
| Cost of revenue | $5.42M | $3.88M | $4.64M | $4.79M | $4.02M |
| Operating income | $11.49M | $16.16M | -$67.23M | $9.20M | -$87.89M |
| EBITDA | $15.17M | $23.22M | $20.33M | $10.33M | $31.66M |
| Net income | $5.03M | $12.09M | -$92.93M | $2.30M | $23.44M |
| EPS (diluted) | $0.02 | $0.05 | $-1.41 | $-3.90 | $-43.05 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $166.13M | $125.41M | $116.54M | $84.75M | $55.66M |
| Total liabilities | $23.85M | $27.00M | $38.06M | $12.54M | $14.57M |
| Shareholders’ equity | $106.03M | $63.32M | -$15.83M | $42.52M | $41.09M |
| Cash and equivalents | $37.07M | $11.81M | $33.51M | $25.18M | $44.35M |
| Long-term debt | $303.0K | $885.0K | $199.0K | $121.0K | $408.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.01M | -$3.64M | $25.89M | $10.68M | $20.76M |
| Capital expenditure | -$1.89M | -$2.73M | -$8.59M | -$5.00M | -$8.45M |
| Free cash flow | -$913.0K | -$6.77M | $17.31M | $5.68M | $12.30M |
| Dividends paid | - | - | - | $45.03M | - |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GYRE | $6.47 | -3.6% | 162.85K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |